sandor

Personal biological sensors make more sense for exercise.
two people can move the same weight in the same motion with utterly different physiological responses.

wood1208 said:

Going forward only way iphone SE will be relevant is by mimicking iPhone 8 edge to edge, top down screen coverage(no home button) to give larger screen area in SE frame. It's ok to have internal one generation behind to keep price down.

i would  fully disagree.

the current body of the SE is what attracted it to me. my 5s was a beast that got dropped, mis-treated & put up with it all.
my SE that i replaced it with is identical.

it does everything i need it to do in a rugged body. if they keep updating it with current internals, i am very happy.

Where is Forbes filter for profit margin?

Total profit is mostly meaningless, profit margin is the mark that matters (think back to the hubalaboo ten years ago with Texaco prints of $10 billion a quarter... yeah it was a large amount, but it only amounted to a 10% margin. Because the oil exploration business is expensive.

It makes for good headlines, but profit margins are what we need to be looking at.

mike1 said:

avon b7 said:

The storage wasn't so much an 'upgrade' as a necessity. I'll bet on on a bigger upgrade this autumn although screen size will be a limiting factor. To have something is better than nothing. If they want to be courageous, then an affordable large screen option should be offered but it would cut into margins.

I would love to see some data as to the primary reason user's purchase an SE. In my limited sample size of about four people, all of them chose it for the screen size. If somebody really wanted the larger screen, the 6S is still available. The monthly cost difference is minimal when spread over the installment plans. 

add a fifth to your sample.

i have an iPhone SE specifically because of the physical size of the device.

Mike Wuerthele said:

sandor said:

Acthar is an example of capitalist greed trumping citizen well-being.
Price rises from $40 a vial in 2001 to $28,000/vial in 2013 and $34,000 in 2014 as new companies bought the rights.
Meanwhile, an off patent version is available in the EU for $8/vial

And Martin Shkreli is currently on trial...

It peaked at $44k a vial for a while just after Mallinckrodt bought Questcor. We haven't been on it in ages, but I still keep a wary eye. In 2008 we used a total of 14 vials in two runs at $24000, and $29000 per vial.

https://www.ftc.gov/news-events/press-releases/2017/01/mallinckrodt-will-pay-100-million-settle-ftc-state-charges-it

...and some wonder why the US healthcare is far and away the highest cost-per-citizen vs. life expectancy/outcomes in the developed world...